Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics
By Kamal Choudhury
Sept 15 (Reuters) - Swiss drugmaker Novartis NOVN.S and drug developer Monte Rosa Therapeutics GLUE.O agreed to an up to $5.7 billion licensing deal to develop treatments for immune-related diseases, the companies said on Monday, marking their second partnership in less than a year
Under the agreement, Monte Rosa will receive $120 million upfront and could earn additional milestone payments and royalties.
Shares of the Boston‑based company jumped 50% in early morning trading after the announcement.
Immune-related diseases occur when the immune system mistakenly attacks healthy tissues, causing inflammation and damage. These hard-to-treat conditions can severely impact patients' quality of life.
The deal grants Novartis exclusive rights to an undisclosed drug‑discovery target and options to license two additional programs from Monte Rosa’s early‑stage immunology portfolio.
The agreement represents "additional validation" of Monte Rosa's molecular glue degrader discovery platform from an existing large‑pharma partner, Wedbush’s Robert Driscoll said.
Monte Rosa’s platform, QuEEN, uses artificial intelligence and machine learning to discover and develop new degraders - small molecules designed to break down disease-causing proteins - which Novartis will take into clinical development and commercialisation.
The deal allows Monte Rosa to leverage Novartis' development capabilities to drive programs forward, and use the cash to achieve important milestones with its wholly-owned pipeline, Driscoll added.
Last year, the companies signed a similar $150 million upfront deal for MRT-6160, an early-stage autoimmune/inflammatory drug, with potential future payments up to $2.1 billion plus royalties on non-U.S. sales.
The agreement is Novartis’ second major deal this month, after an up‑to‑$5.2 billion tie‑up with China’s Argo Biopharmaceutical for experimental heart drugs.
Monte Rosa shares had fallen about 31% year-to-date till Friday close.
Related Articles
September Global Central Bank Divergence: How Will U.S. Stocks and Forex Markets Move?
TradingKey - Despite the divergence in monetary policies among major global central banks in September (with the Federal Reserve cutting rates while the European Central Bank, Bank of England, and Bank of Japan maintain steady rates), we expect the policy directions of the Fed, ECB, and BoE to...
Duolingo (DUOL): Can the Green Bird Fly High Again
TradingKey - Duolingo is a great business, despite the stock price being down nearly 50% from its peak less than four months ago. However, the question is whether it’s worth buying it at a market cap of $12.5 billion. The answer is “not yet” because the traffic, even though healthy...
U.S. September Rate Decision Preview: What It Means for Bitcoin and Could It Spark a New Rally?
Bitcoin’s rally stalls ahead of the Fed meeting — has the bullish momentum already been priced in?
UK July GDP Commentary: Can GBP Break Through Its Current Fluctuation?
After considering multiple factors, given the evident weakness on both sides of this currency pair, we expect the GBP/USD exchange rate to maintain its current fluctuation trend in the short term.
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.
